Search company, investor...

Guilford Pharmaceuticals

Founded Year



Acq - P2P | Acquired

Total Raised


About Guilford Pharmaceuticals

Guilford Pharmaceuticals is a pharmaceutical company engaged in the research, development and commercialization of products that target the hospital market. Guilford's marketed products include the Gliadel Wafer for brain tumor treatment, and their product pipeline includes a novel anesthetic, Aquavan Injection.

Headquarters Location

6611 Tributary Street Suite 100

Baltimore, Maryland, 21224,

United States


Missing: Guilford Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Guilford Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Guilford Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Guilford Pharmaceuticals is included in 1 Expert Collection, including Cancer.



1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Guilford Pharmaceuticals Patents

Guilford Pharmaceuticals has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Polymers, Drug delivery devices, Nanomaterials, Dosage forms, Membrane biology


Application Date


Grant Date



Related Topics

Polymers, Drug delivery devices, Nanomaterials, Dosage forms, Membrane biology



Guilford Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Guilford Pharmaceuticals founded?

    Guilford Pharmaceuticals was founded in 1993.

  • Where is Guilford Pharmaceuticals's headquarters?

    Guilford Pharmaceuticals's headquarters is located at 6611 Tributary Street, Baltimore.

  • What is Guilford Pharmaceuticals's latest funding round?

    Guilford Pharmaceuticals's latest funding round is Acq - P2P.

  • How much did Guilford Pharmaceuticals raise?

    Guilford Pharmaceuticals raised a total of $131.86M.

  • Who are the investors of Guilford Pharmaceuticals?

    Investors of Guilford Pharmaceuticals include MGI Pharma, Domain Associates, Merlin Biomed Group, Highbridge Capital Management, Quogue Capital and 34 more.

  • Who are Guilford Pharmaceuticals's competitors?

    Competitors of Guilford Pharmaceuticals include Bellus Health, Aquinox Pharmaceuticals, Auxilium Pharmaceuticals, Cadence Pharmaceuticals, Topaz Pharmaceuticals and 13 more.

Compare Guilford Pharmaceuticals to Competitors

IVREA Pharmaceuticals

IVREA Pharmaceuticals is a specialty pharmaceutical company focused on clinical development and commercialization of novel prescription pharmaceuticals for the treatment of dermatologic conditions. IVREA's pharmaceuticals leverage topical delivery technologies.

Frio Pharmaceuticals

Frio Pharmaceuticals is dedicated to oral-systemic health and was spun out of Biomedical Development Corporation (BDC), its research affiliate, in 1999 to manufacture and sell a dental waterline cleaner. This platform technology has evolved into a pipeline of pharmaceuticals to treat oral diseases and interrupt the disease process. Its goal is to commercialize a broad-spectrum antimicrobial platform technology with products being: (1) a pharmaceutical to treat thrush (oral candidiasis) in cancer patients with thrush and (2) a pharmaceutical to treat gingivitis (oral inflammation).


Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.

SpePharm Holding

A European specialty pharmaceutical company dedicated to hospital and specialist drugs.SpePharm is a European specialty pharmaceutical company focused on acquiring, registering and marketing high medical value specialty medicines, essentially for the hospital market.

Slate Pharmaceuticals

Slate currently markets Testopel in the United States. Testopel is an FDA-approved subcutaneous implantable testosterone pellet. Testopel is used for the treatment of testosterone deficiency in aging men as well as androgen deficiency caused by other conditions.

Urigen Pharmacueticals

Urigen specializes in the design and commercialization of innovative products for patients with urological ailments. The company develops products for amelioration of Painful Bladder Syndrome (PBS), Urethritis, Nocturia and Over Active Bladder (OAB).

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.